| Autor: |
Miyata Y; Department of Surgery, Asahi General Hospital, 1326 I, Asahi-shi, Chiba 289-2511, Japan.; Department of Surgery, National Defence Medical College, 3-2 Namiki, Tokorozawa-shi, Saitama 359-8513, Japan., Kogure R; Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Centre, Kamoda 1981, Kawagoe-shi, Saitama 350-5500, Japan., Nakazawa A; Department of Surgery, National Defence Medical College, 3-2 Namiki, Tokorozawa-shi, Saitama 359-8513, Japan., Nagata R; Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 13-8655, Japan., Mitsui T; Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Centre, Kamoda 1981, Kawagoe-shi, Saitama 350-5500, Japan., Ninomiya R; Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Centre, Kamoda 1981, Kawagoe-shi, Saitama 350-5500, Japan., Komagome M; Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Centre, Kamoda 1981, Kawagoe-shi, Saitama 350-5500, Japan., Maki A; Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Centre, Kamoda 1981, Kawagoe-shi, Saitama 350-5500, Japan., Kawarabayashi N; Department of Surgery, Gyoda General Hospital, Mochida 376, Gyoda-shi, Saitama 361-0056, Japan., Beck Y; Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Centre, Kamoda 1981, Kawagoe-shi, Saitama 350-5500, Japan. |
| Abstrakt: |
Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between patients who received S-1 as adjuvant chemotherapy (S-1 group) and those who underwent surgical treatment alone (observation group). Of 170 eligible patients, 38 patients were selected in each group after propensity score matching. Among those in the matched cohort, both the median recurrence-free survival (RFS) and overall survival (OS) in the S-1 group were significantly longer than those in the observation group (RFS, 61.2 vs. 13.1 months, p = 0.033; OS, not available vs. 28.2 months, p = 0.003). A multivariate analysis of the OS revealed that perineural invasion and adjuvant S-1 chemotherapy were independent prognostic factors. According to a subgroup analysis of the OS, the S-1 group showed significantly better prognoses than the observation group among patients with perineural invasion ( p < 0.001). S-1 adjuvant chemotherapy might improve the prognosis of BTC, especially in patients with perineural invasion. |
